Leslie Holsinger's most recent trade in Quince Therapeutics Inc was a trade of 10,920 Common Stock done at an average price of $2.9 . Disclosure was reported to the exchange on June 6, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Quince Therapeutics Inc | Leslie Holsinger | EVP, Preclinical Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.86 per share. | 06 Jun 2022 | 10,920 | 148,080 (0%) | 0% | 2.9 | 31,231 | Common Stock |
| Quince Therapeutics Inc | Leslie Holsinger | EVP, Preclinical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 155,500 | 159,000 (0%) | 0% | 0 | Common Stock | |
| Quince Therapeutics Inc | Leslie Holsinger | EVP, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 125,000 | 125,000 | - | - | Stock option (right to buy) | |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2020 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2020 | 40,000 | 66,794 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.27 per share. | 11 Dec 2020 | 40,000 | 43,500 (0%) | 0% | 0.3 | 10,800 | Common Stock |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Sale of securities on an exchange or to another person at price $ 30.15 per share. | 11 Dec 2020 | 14,275 | 27,525 (0%) | 0% | 30.1 | 430,391 | Common Stock |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Sale of securities on an exchange or to another person at price $ 30.91 per share. | 11 Dec 2020 | 13,200 | 14,325 (0%) | 0% | 30.9 | 408,012 | Common Stock |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Sale of securities on an exchange or to another person at price $ 31.79 per share. | 11 Dec 2020 | 9,525 | 1,800 (0%) | 0% | 31.8 | 302,800 | Common Stock |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Sale of securities on an exchange or to another person at price $ 28.80 per share. | 11 Dec 2020 | 1,700 | 41,800 (0%) | 0% | 28.8 | 48,960 | Common Stock |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Sale of securities on an exchange or to another person at price $ 32.59 per share. | 11 Dec 2020 | 900 | 3,500 (0%) | 0% | 32.6 | 29,331 | Common Stock |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Sale of securities on an exchange or to another person at price $ 32.58 per share. | 11 Dec 2020 | 400 | 4,400 (0%) | 0% | 32.6 | 13,034 | Common Stock |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2020 | 3,500 | 106,794 | - | - | Stock Option (Right to Buy) | |
| Quince Therapeutics Inc | Leslie Holsinger | Executive Vice President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.27 per share. | 10 Dec 2020 | 3,500 | 3,500 (0%) | 0% | 0.3 | 945 | Common Stock |